GenVec

GenVec is a clinical-stage biopharmaceutical company focusing on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform. It designs, tests and manufactures adenoviral-based product candidates. The Company’s lead product candidate is CGF166, which is in Phase I, II clinical trial for the treatment of hearing loss and balance disorders.